NCODA member Chris Kepinski, clinical oncology pharmacy manager for Southern Oncology Specialists in North Carolina, recently spoke on a national panel regarding advancing quality in oncology care as part of the Institute for Value-Based Medicine, a new initiative of The American Journal of Managed Care.
Read entire article in AJMC Here
The addition of abemaciclib (Verzenio) to initial treatment with a nonsteroidal aromatase inhibitor appeared effective for women with hormone receptor-positive, HER-2-negative advanced breast cancer, according to results of the double-blind, phase 3 MONARCH 3 study presented at American Association for Cancer Research Annual Meeting.
Accumulator programs target specialty drugs for which a manufacturer provides copayment assistance. Unlike conventional benefit designs, the manufacturer’s payments no longer count toward a patient’s deductible or out-of-pocket maximum. Plan sponsors (employers and health plans) will save big money because accumulators shift a majority of drug costs to patients and manufacturers. Accumulator programs will further lower a plan’s drug spending by discouraging the appropriate utilization of specialty therapies and reducing adherence.
By Joshua Nubla, PharmD; Neal Dave, PharmD; and Michael Reff, RPh, MBA
An in-depth look into a nationwide collaborative initiative to standardize and improve oncology dispensing practices for the benefit of patient/provider education, adherence, and overall care.
Care for patients in the oncology setting is extremely diverse and complex. Management of the many distinct oral oncolytic regimens through pharmacy dispensing platforms in clinical practice can leave gaps within the healthcare system that should be addressed. These gaps are not caused by knowledge gaps; they result from a lack of contact with consistent and updated education material that succinctly describes and explains the primary details of treatment with specific medications, including but not limited to compliance obstacles and solutions, instructions on managing side effects and major adverse effects, and expectations of therapeutic onset and duration. Read article here.
Passion for Patients
